PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation

Deciphering the chronology of copy number alterations in Multiple Myeloma

(2019) Anil Aktas Samur et al.   Blood Cancer Journal

Understanding histone H3 lysine 36 methylation and its deregulation in disease

(2019) Jie Li et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

lncRNA-Induced Spread of Polycomb Controlled by Genome Architecture, RNA Abundance, and CpG Island DNA

(2019) Megan D. Schertzer et al.   MOLECULAR CELL

PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism

(2019) Siddhant U. Jain et al.   Nature Communications

Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

(2019) Zhimin Gu et al.   Cancer Discovery

The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells

(2018) Gundula Streubel et al.   MOLECULAR CELL

Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding

(2018) Siming Chen et al.   MOLECULAR CELL

Capturing the Onset of PRC2-Mediated Repressive Domain Formation

(2018) Ozgur Oksuz et al.   MOLECULAR CELL

MTF2 recruits Polycomb Repressive Complex 2 by helical-shape-selective DNA binding

(2018) Matteo Perino et al.   NATURE GENETICS

The multiple myelomas — current concepts in cytogenetic classification and therapy

(2018) Shaji K. Kumar et al.   Nature Reviews Clinical Oncology

Signalling crosstalk during early tumorigenesis in the absence of Polycomb silencing

(2018) Jorge V. Beira et al.   PLoS Genetics

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer

(2018) Ling Cai et al.   MOLECULAR CELL

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

(2018) Laurie Herviou et al.   Clinical Epigenetics

Polycomb-like proteins link the PRC2 complex to CpG islands

(2017) Haojie Li et al.   NATURE

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

(2017) Faizaan Mohammad et al.   NATURE MEDICINE

DNA binding by PHF1 prolongs PRC2 residence time on chromatin and thereby promotes H3K27 methylation

(2017) Jeongyoon Choi et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

DNA binding by PHF1 prolongs PRC2 residence time on chromatin and thereby promotes H3K27 methylation

(2017) Jeongyoon Choi et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

(2017) Teresa Ezponda et al.   Cell Reports

Indicators of responsiveness to immune checkpoint inhibitors

(2017) Bradley D. Shields et al.   Scientific Reports

Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development

(2016) Rui Lu et al.   CANCER CELL

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition

(2016) Goro Sashida et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

(2016) Jonathan S. Mitchell et al.   Nature Communications

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

(2016) Prasoon Agarwal et al.   Oncotarget

Polycomb genes, miRNA, and their deregulation in B-cell malignancies

(2015) G. G. Wang et al.   BLOOD

Targeting EZH2 and PRC2 dependence as novel anticancer therapy

(2015) Bowen Xu et al.   EXPERIMENTAL HEMATOLOGY

Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma

(2015) Deepanwita Sengupta et al.   MOLECULAR & CELLULAR PROTEOMICS

EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes

(2015) H. Hernando et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Polycomb systems to regulate gene expression: modifications to a complex story

(2015) Neil P. Blackledge et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2

(2015) L. Jiao et al.   SCIENCE

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

(2014) B. Xu et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Role of PRC2-associated factors in stem cells and disease

(2014) Pedro Vizán et al.   FEBS Journal

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

(2014) C J Heuck et al.   LEUKEMIA

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

(2014) William Lee et al.   NATURE GENETICS

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

(2014) Relja Popovic et al.   PLoS Genetics

An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1

(2013) Kyle D. Konze et al.   ACS Chemical Biology

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

(2013) Wendy Béguelin et al.   CANCER CELL

Transcriptional regulation by Polycomb group proteins

(2013) Luciano Di Croce et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

(2013) P. W. Lewis et al.   SCIENCE

Tudor: a versatile family of histone methylation ‘readers’

(2013) Rui Lu et al.   TRENDS IN BIOCHEMICAL SCIENCES

Recurrent Rearrangement of the PHF1 Gene in Ossifying Fibromyxoid Tumors

(2012) Samuel Gebre-Medhin et al.   AMERICAN JOURNAL OF PATHOLOGY

A687V EZH2 is a gain-of-function mutation found in lymphoma patients

(2012) Christina R. Majer et al.   FEBS LETTERS

A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia

(2012) C. Simon et al.   GENES & DEVELOPMENT

An H3K36 Methylation-Engaging Tudor Motif of Polycomb-like Proteins Mediates PRC2 Complex Targeting

(2012) Ling Cai et al.   MOLECULAR CELL

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

(2012) Panagiotis Ntziachristos et al.   NATURE MEDICINE

Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity

(2012) Cecilia Ballaré et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation

(2012) Gerard L Brien et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Novel Fusion of MYST/Esa1-Associated Factor 6 and PHF1 in Endometrial Stromal Sarcoma

(2012) Ioannis Panagopoulos et al.   PLoS One

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

(2012) M. T. McCabe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3

(2012) Y. Zheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Polycomb-Like 3 Promotes Polycomb Repressive Complex 2 Binding to CpG Islands and Embryonic Stem Cell Self-Renewal

(2012) Julie Hunkapiller et al.   PLoS Genetics

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Druggability of methyl-lysine binding sites

(2011) C. Santiago et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

The Polycomb complex PRC2 and its mark in life

(2011) Raphaël Margueron et al.   NATURE

Jarid2 and PRC2, partners in regulating gene expression

(2010) G. Li et al.   GENES & DEVELOPMENT

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells

(2010) Diego Pasini et al.   NATURE

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

(2010) Rajnish A. Gupta et al.   NATURE

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

(2010) Ryan D Morin et al.   NATURE GENETICS

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

(2010) C. J. Sneeringer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Jarid2/Jumonji Coordinates Control of PRC2 Enzymatic Activity and Target Gene Occupancy in Pluripotent Cells

(2009) Jamy C. Peng et al.   CELL

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

(2008) H. Rozemuller et al.   HAEMATOLOGICA

Ezh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo

(2008) K. Sarma et al.   MOLECULAR AND CELLULAR BIOLOGY